SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Haematologica. 2021;106(8):2277-2280.

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.

, , , , , , , , ,

제1저자 김미소 · 교신저자 김태민

PMID 33792222 PMC8327727 DOI 10.3324/haematol.2021.278301 IF 8.2 혈액종양내과
소속 (5)
  1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul.
  2. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam.
  3. Department of Pathology, Seoul National University Hospital, Seoul.
  4. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul. gabriel9@snu.ac.kr.
  5. Seoul National University Cancer Research Institute, Seoul, Republic of Korea; Department of Pathology, Seoul National University Hospital, Seoul.

Figures

Figure 1.
Figure 1. Response to brentuximab vedotin. Waterfall plot of maximum percent change in tumor size of target lesions from baseline. NK: natural killer; NOS: not otherwise specified; EBV: Epstein-Barr virus; DLBCL: diffuse large B-cell lymphoma.
Figure 2.
Figure 2. Mutational profiles of 14 patients in this trial. Samples for 14 patients, including four pairs of sequentially acquired samples, were subjected to targeted sequencing encompassing 120 lymphoma-associated genes. *Patient SNU22 was initially diagnosed as having extranodal NK/T-cell lymphoma according to the patient’s referral record from another hospital. CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; AITL: angioimmunoblastic T-cell lymphoma; PTCL: peripheral T-cell lymphoma; ENKTCL: extranodal NK/T-cell lymphoma, nasal type; EBV+ LPD: Epstein-Barr virus-positive Tcell lymphoproliferative disorders.

그림 출처: PubMed Central 공개 논문 (PMC8327727)

그 밖의 정보
출판 형태
Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
저널
Haematologica · eISSN 1592-8721
전자 출판
2021-08-01
MeSH
Brentuximab Vedotin · Epstein-Barr Virus Infections* / complications / drug therapy · Herpesvirus 4, Human · Humans · Immunoconjugates* / therapeutic use · Ki-1 Antigen · Lymphoma*
Substances
Immunoconjugates · Ki-1 Antigen · Brentuximab Vedotin
데이터
ClinicalTrials.gov: NCT02388490
참고문헌
15편